Beijing Institute of Respiratory Medicine, Capital Medical University, Beijing 100069, China.
Toxicology. 2013 Feb 8;304:158-66. doi: 10.1016/j.tox.2012.12.020. Epub 2013 Jan 8.
Acute lung injury (ALI) has many possible etiopathologies and is characterized by acute diffuse lung damage with poor prognosis. Lipopolysaccharide (LPS) is widely used as septic model of ALI in pharmacological research. This study compares intratracheal bolus instillation (IT) with dose-adjusted aerosol inhalation (IH) of LPS in Wistar rats using both non-invasive and terminal endpoints. The former comprised exhaled nitric oxide (NOE) and 'enhanced pause' (Penh) both measured in spontaneous breathing conscious rats. Terminal endpoints included lung weights, LDH, protein, total cell counts, and cytodifferentiation in bronchoalveolar lavage (BAL). Measurements were made 1, 3, 7, and 14 days after IT instillation (5 mg LPS/kg body weight) or 6-hour directed-flow nose-only inhalation exposure to respirable LPS-aerosol at 100 mg/m(3) (thoracic dose: 2.6 mgLPS/kg body weight). Controls received saline (IT) or air only (IH). LDH and protein were significantly different from the control in the LPS-IH group (days 1 and 3) with a somewhat inconclusive outcome in the LPS-IT group due to the effects occurring in the control. Total cell counts were equally elevated with similar time-course changes in the LPS-IT and -IH groups. Polymorphonuclear neutrophils (PMNs) were indistinguishable amongst LPS-dosed rats. Again, IT-dosed control rats displayed markedly higher background levels than those dosed by inhalation. Similarly NOE was significantly elevated on post-LPS day 1 as was Penh. In summary, the LPS-aerosol dose delivered by nose-only exposure over 6 h was equally potent as the 2-times higher LPS-IT bolus dose on post-LPS day 1 with somewhat faster recovery thereafter. The climax and discriminatory power of the non-invasive endpoints matched those determined terminally. This supports the conclusion that the pharmacological efficacy and side effects of inhalation pharmaceuticals designed to mitigate ALI can better be identified by LPS-aerosol than by LPS-IT. Non-invasive time-course measurements may deliver apt information both on the efficacious dose as well as the dosing intervals required to maintain the targeted efficacy using a minimum of experimental animals. The outcome of this comparative study supports the conclusion that the inhalation route produces a more uniform type of injury at lower, more meaningful dosages. When designing studies for screening of effective drugs this mode of delivery appears to better approximate the human condition with less dosimetric uncertainty, less experimental variability and better characterization of what was actually delivered to the entire respiratory tract.
急性肺损伤 (ALI) 有许多可能的病因,其特征是急性弥漫性肺损伤,预后不良。脂多糖 (LPS) 广泛用于药理学研究中的 ALI 败血症模型。本研究比较了气管内推注 (IT) 和剂量调整的雾化吸入 (IH) 在 Wistar 大鼠中的作用,使用了非侵入性和终末终点。前者包括呼气一氧化氮 (NOE) 和自发呼吸清醒大鼠的“增强暂停” (Penh)。终末终点包括肺重、LDH、蛋白质、总细胞计数和支气管肺泡灌洗 (BAL) 中的细胞分化。在 IT 注射 (5mg LPS/kg 体重) 或可吸入 LPS 气溶胶 6 小时定向流量鼻内暴露后 1、3、7 和 14 天进行测量 (呼吸剂量:2.6mg LPS/kg 体重)。对照组接受盐水 (IT) 或仅空气 (IH)。与对照组相比,LPS-IH 组的 LDH 和蛋白质明显不同 (第 1 天和第 3 天),而 LPS-IT 组的结果则不太确定,因为对照组也出现了这种情况。总细胞计数在 LPS-IT 和 -IH 组中同样升高,具有相似的时间过程变化。多形核白细胞 (PMN) 在 LPS 给药大鼠中无法区分。同样,IT 给药的对照大鼠显示出比吸入给药更高的背景水平。同样,NOE 在 LPS 后第 1 天显著升高,Penh 也升高。总之,6 小时内通过鼻内暴露给予的 LPS 气溶胶剂量与 LPS-IT 冲击剂量的 2 倍高剂量在 LPS 后第 1 天同样有效,此后恢复速度稍快。非侵入性终点的高潮和区分力与终端确定的终点相匹配。这支持了这样的结论,即设计用于减轻 ALI 的吸入药物的药理学功效和副作用可以通过 LPS 气溶胶而不是 LPS-IT 更好地识别。非侵入性时间过程测量可以提供有关有效剂量以及维持靶向功效所需的给药间隔的适当信息,使用的实验动物最少。这项比较研究的结果支持这样的结论,即吸入途径在更低、更有意义的剂量下产生更均匀的损伤类型。在设计用于筛选有效药物的研究时,这种给药方式似乎更能接近人类的情况,剂量不确定性更小,实验变异性更小,对实际输送到整个呼吸道的药物的描述更好。